Copertina

Artificial intelligence streamlines scientific discovery of drug–target interactions

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yuxin Yang, Feixiong Cheng
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	British Journal of Pharmacology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

EpigenPlot: An interactive web platform for DNA methylation‐based biomarker and drug target discovery in colorectal cancer
di: Dalma Müller, et al.
Pubblicazione: (2025)

Natural products and cancer: From drug discovery to prevention and therapy
di: Angelo A. Izzo, et al.
Pubblicazione: (2025)

Unravelling the multifaceted actions of neurosteroids: Machine learning and in vitro screening for novel target discovery
di: Ajeet Kumar, et al.
Pubblicazione: (2025)

The use of different types of networks, alone and in combination, for drug target identification
di: Paolo Parini
Pubblicazione: (2025)

A computer‐aided drug repurposing: the antibacterial agents targeting GroEL
di: Dongdong Zhang, et al.
Pubblicazione: (2025)

Systematic drug screening and target analysis identify digitoxin as a potential therapy for uveal melanoma
di: Huilin Liu, et al.
Pubblicazione: (2024)

Altered desensitization and internalization patterns of rodent versus human glucose‐dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge
di: Lærke Smidt Gasbjerg, et al.
Pubblicazione: (2024)

MicroRNA‐guided drug discovery for mitigating persistent pulmonary complications in critical COVID‐19 survivors: A longitudinal pilot study
di: María C. García‐Hidalgo, et al.
Pubblicazione: (2024)

Pharmacology and relevant drug interactions of metamizole
di: David J. Brinkman, et al.
Pubblicazione: (2025)

Non‐canonical nitric oxide signalling and DNA methylation: Inflammation induced epigenetic alterations and potential drug targets
di: Christopher H. Switzer
Pubblicazione: (2024)

Experience of a nirmatrelvir/ritonavir drug–drug interaction expert advice service
Pubblicazione: (2024)

Evaluation of artificial intelligence‐generated drug therapy communication skill competencies in medical education
di: Kannan Sridharan, et al.
Pubblicazione: (2024)

Targeted peptide‐modified M2 exosomes drug delivery system for the targeted regulation of the lung injury microenvironment with isorhynchophylline (IRN): based on the inflammatory–metabolic–epigenetic synergy mechanism
di: Jin‐Ru Zou, et al.
Pubblicazione: (2026)

Predicting drug–drug interactions between ainuovirine and rifampicin plus isoniazid using PBPK modelling
Pubblicazione: (2024)

A case report highlighting drug–drug interactions between 3 life‐saving treatments: Feminizing hormones, antiretrovirals and antituberculosis drugs
di: Tara Suchak, et al.
Pubblicazione: (2024)

Exploring the link between antihypertensive drugs targets and pancreatitis risk through Mendelian randomization
di: Zhiwei Du, et al.
Pubblicazione: (2025)

Structure‐based discovery of thiamine uptake inhibitors
di: Florian Gabriel, et al.
Pubblicazione: (2025)

Pharmacokinetic drug–drug interactions with flucloxacillin and other isoxazolyl penicillins: A systematic literature review and practical guide
di: Julia M. Wortman, et al.
Pubblicazione: (2026)

Clinical pharmacology considerations and drug–drug interactions with long‐acting cabotegravir and rilpivirine relevant to sub‐Saharan Africa
di: Adrian Steulet, et al.
Pubblicazione: (2024)

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy
di: Tjitske M. van der Zanden, et al.
Pubblicazione: (2026)

Evaluating the capability of ChatGPT in predicting drug–drug interactions: Real‐world evidence using hospitalized patient data
di: Ramya Padmavathy Radha Krishnan, et al.
Pubblicazione: (2024)

Single‐dose and steady‐state pharmacokinetics of clomipramine, yohimbine and clomipramine/yohimbine combination: A clinical drug–drug interaction study
di: Amelie Leutzendorff, et al.
Pubblicazione: (2024)

In depth: The drug interaction between trimethoprim‐sulfamethoxazole and folic acid/folinic acid
di: Emmy Boerrigter, et al.
Pubblicazione: (2024)

Advancing antihypertensive drug development
di: Fay Pu, et al.
Pubblicazione: (2025)

Novel approaches for the discovery of pharmacogenetic biomarkers of chemotoxicity in patients with colorectal cancer
di: Ana Rita Simoes, et al.
Pubblicazione: (2025)

Have plastic culture models prevented the discovery of effective cancer therapeutics?
di: Kevin M. Tharp
Pubblicazione: (2024)

Drug–drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450
di: Vivek S. Purohit, et al.
Pubblicazione: (2025)

Quantitative prediction of intravenous drug interactions caused by cytochromes P450 inhibitors and inducers
di: Vianney Tuloup, et al.
Pubblicazione: (2026)

Assessing ChatGPT's capability in understanding and reporting antiretroviral therapy drug–drug interaction effects: Quantitative and qualitative results from the ACCURATE‐DDI study
di: E. Ready, et al.
Pubblicazione: (2025)

Lack of clinically significant drug–drug interactions between the third‐generation integrase strand transfer inhibitor VH4524184 (VH‐184) and combined oral contraceptives
di: E. Doyle, et al.
Pubblicazione: (2025)

A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam
di: Jane Knöchel, et al.
Pubblicazione: (2024)

Alternative splicing with CYP3A4*22: Implications for the steroid‐tacrolimus drug interaction
di: Jana Stojanova, et al.
Pubblicazione: (2025)

Inflammation‐mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis
di: Svetlana Agachi, et al.
Pubblicazione: (2024)

Drug–drug interactions between gender‐affirming hormone therapy and antiretrovirals for treatment/prevention of HIV
di: Tessa Senneker
Pubblicazione: (2024)

Biodiversity2Drugs—Renaissance of exploring nature‐derived peptides for GPCR ligand discovery
di: Christian W. Gruber, et al.
Pubblicazione: (2025)

Opportunities of patient‐derived organoids in drug development
di: Antonia Büning, et al.
Pubblicazione: (2025)

Genetic polymorphisms influencing antihypertensive drug responses
di: Jana El Cheikh, et al.
Pubblicazione: (2024)

Chemistry/structural biology of psychedelic drugs and their receptor(s)
di: Ryan H. Gumpper, et al.
Pubblicazione: (2024)

Emerging therapeutic opportunities for psychedelic and related drugs
di: Susan Wonnacott, et al.
Pubblicazione: (2026)

Investigation of a broad‐spectrum micronutrient formulation as a possible precipitant of pharmacokinetic micronutrient–drug interactions
di: Bess M. Kew, et al.
Pubblicazione: (2025)